Sign in to view content

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2022

Related

Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2021
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
John W. Kitchens, MD
Annual Meeting Talks
2021
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion:72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Updates from the Field
2024

Category: AMD-Neovascular

See more